DTX2 and hepatocellular carcinoma: Targeting DTX2 decreased the related histone epigenetic modifications of CXCL2 and CXCL6, thereby attenuating the immunosuppressive characteristics of the TME and sensitizing HCC cells to anti‐PD1 immunotherapy.